BRAINLIFE Brain Tumor Medical Database
Home Page  Archive of Issues


Volume 12 Number 2
 February 2012

Home > Current Neuro-Oncology > Volume 12 - Year 2012 > Number 2, February 2012

Contents



Classification

Page TopPage Bottom


Hegi ME, Janzer RC, Lambiv WL, Gorlia T, Kouwenhoven MC, Hartmann C, von Deimling A, Martinet D, Besuchet Schmutz N, Diserens AC, Hamou MF, Bady P, Weller M, van den Bent MJ, Mason WP, Mirimanoff RO, Stupp R, Mokhtari K, Wesseling P.
Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial.
Acta Neuropathol. 2012 Jan 15. [Epub ahead of print]


Diagnosis

Page TopPage Bottom


Arbizu J, Tejada S, Marti-Climent JM, Diez-Valle R, Prieto E, Quincoces G, Vigil C, Idoate MA, Zubieta JL, Peñuelas I, Richter JA.
Quantitative volumetric analysis of gliomas with sequential MRI and (11)C-methionine PET assessment: patterns of integration in therapy planning.
Eur J Nucl Med Mol Imaging. 2012 Jan 19. [Epub ahead of print]


Epidemiology

Page TopPage Bottom


Crocetti E, Trama A, Stiller C, Caldarella A, Soffietti R, Jaal J, Weber DC, Ricardi U, Slowinski J, Brandes A; RARECARE working group.
Epidemiology of glial and non-glial brain tumours in Europe.
Eur J Cancer. 2012 Jan 6. [Epub ahead of print]

Dobes M, Khurana VG, Shadbolt B, Jain S, Smith SF, Smee R, Dexter M, Cook R.
Increasing incidence of glioblastoma multiforme and meningioma, and decreasing incidence of Schwannoma (2000-2008): Findings of a multicenter Australian study.
Surg Neurol Int. 2011;2:176. Epub 2011 Dec 13.

Sun T, Warrington NM, Rubin JB.
Why Does Jack and not Jill Break His Crown: Sex Disparity in Brain Tumors.
Biol Sex Differ. 2012 Jan 25;3(1):3. [Epub ahead of print]


Etiology & Pathogenesis

Page TopPage Bottom


Bangert A, Cristofanon S, Eckhardt I, Abhari BA, Kolodziej S, Häcker S, Vellanki SH, Lausen J, Debatin KM, Fulda S.
Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP.
Oncogene. 2012 Jan 23. doi: 10.1038/onc.2011.614. [Epub ahead of print]

Bleeker FE, Molenaar RJ, Leenstra S.
Recent advances in the molecular understanding of glioblastoma.
J Neurooncol. 2012 Jan 20. [Epub ahead of print]

Lee D, Kang SY, Suh YL, Jeong JY, Lee JI, Nam DH.
Clinicopathologic and genomic features of gliosarcomas.
J Neurooncol. 2012 Jan 20. [Epub ahead of print]

Rausch T, Jones DT, Zapatka M, Stütz AM, Zichner T, Weischenfeldt J, Jäger N, Remke M, Shih D, Northcott PA, Pfaff E, Tica J, Wang Q, Massimi L, Witt H, Bender S, Pleier S, Cin H, Hawkins C, Beck C, von Deimling A, Hans V, Brors B, Eils R, Scheurlen W, Blake J, Benes V, Kulozik AE, Witt O, Martin D, Zhang C, Porat R, Merino DM, Wasserman J, Jabado N, Fontebasso A, Bullinger L, Rücker FG, Döhner K, Döhner H, Koster J, Molenaar JJ, Versteeg R, Kool M, Tabori U, Malkin D, Korshunov A, Taylor MD, Lichter P, Pfister SM, Korbel JO.
Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations.
Cell. 2012 Jan 20;148(1-2):59-71.

Rodriguez FJ, Orr BA, Ligon KL, Eberhart CG.
Neoplastic cells are a rare component in human glioblastoma microvasculature.
Oncotarget. 2012 Jan 30;. [Epub ahead of print]

Taylor TE, Furnari FB, Cavenee WK.
Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome Resistance.
Curr Cancer Drug Targets. 2012 Jan 16. [Epub ahead of print]


Prognosis

Page TopPage Bottom


Iliadis G, Kotoula V, Chatzisotiriou A, Televantou D, Eleftheraki AG, Lambaki S, Misailidou D, Selviaridis P, Fountzilas G.
Volumetric and MGMT parameters in glioblastoma patients: Survival analysis.
BMC Cancer. 2012 Jan 3;12:3.

Montano N, Cenci T, Martini M, D'Alessandris QG, Pelacchi F, Ricci-Vitiani L, Maira G, De Maria R, Larocca LM, Pallini R.
Expression of EGFRvIII in Glioblastoma: Prognostic Significance Revisited.
Neoplasia. 2011 Dec;13(12):1113-21.

Rock K, McArdle O, Forde P, Dunne M, Fitzpatrick D, O'Neill B, Faul C.
A clinical review of treatment outcomes in glioblastoma multiforme - the validation in a non-trial population of the results of a randomised Phase III clinical trial: has a more radical approach improved survival?
Br J Radiol. 2012 Jan 3. [Epub ahead of print]


Treatment


Laboratory Investigations

Page TopPage Bottom


Niles LP, Sathiyapalan A, Bahna S, Kang NH, Pan Y.
Valproic acid up-regulates melatonin MT1 and MT2 receptors and neurotrophic factors CDNF and MANF in the rat brain.
Int J Neuropsychopharmacol. 2012 Jan 16:1-8. [Epub ahead of print]

Pechman KR, Donohoe DL, Bedekar DP, Kurpad SN, Schmainda KM.
Evaluation of combined bevacizumab plus irinotecan therapy in brain tumors using magnetic resonance imaging measures of relative cerebral blood volume.
Magn Reson Med. 2011 Dec 28. doi: 10.1002/mrm.23315. [Epub ahead of print]


Clinical Investigations

Page TopPage Bottom


Couec ML, André N, Thebaud E, Minckes O, Rialland X, Corradini N, Aerts I, Bérard PM, Bourdeaut F, Leblond P; on the behalf of the Comité Pharmacologie of the SFCE.
Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: Toxicity and efficacy trends.
Pediatr Blood Cancer. 2012 Jan 27. doi: 10.1002/pbc.24066. [Epub ahead of print]

Haar CP, Hebbar P, Wallace GC 4th, Das A, Vandergrift WA 3rd, Smith JA, Giglio P, Patel SJ, Ray SK, Banik NL.
Drug Resistance in Glioblastoma: A Mini Review.
Neurochem Res. 2012 Jan 10. [Epub ahead of print]

Marosi C.
Complications of chemotherapy in neuro-oncology.
Handb Clin Neurol. 2012;105:873-85.

Vauleon E, Mesbah H, Gedouin D, Lecouillard I, Louvel G, Hamlat A, Riffaud L, Carsin B, Quillien V, Audrain O, Lesimple T.
Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab.
Bull Cancer. 2012 Jan 17. [Epub ahead of print]

Warrington JP, Csiszar A, Mitschelen M, Lee YW, Sonntag WE.
Whole brain radiation-induced impairments in learning and memory are time-sensitive and reversible by systemic hypoxia.
PLoS One. 2012;7(1):e30444. Epub 2012 Jan 18.


Treatment Overviews

Page TopPage Bottom


Timotheadou E.
New agents targeting angiogenesis in glioblastoma.
Chemother Res Pract. 2011;2011:878912.


Patients & Caregivers

Page TopPage Bottom


International Brain Tumour Alliance
IBTA E-News January 2012

Page Top


This website is certified by Health On the Net Foundation. Click to verify. HOME CURRENT NEURO-ONCOLOGY CLINICAL NEURO-ONCOLOGY LIBRARY
DATABASE: Classification | Diagnosis | Epidemiology | Etiology & Pathogenesis | Integrative Medicine | Overall Management | Prognosis | Psychosocial Aspects | Stem Cells | Treatment
SERVICES
: About BrainLife | Children's Corner | E-mail Alerts | Journals | Links |
Motto, Dedication, etc. | Patients & Caregivers | Privacy Policy | Search | SiteMap bottom
This site complies with the HONcode standard for trustworthy health information: verify here